Acadia Pharmaceuticals (ACAD) Current Leases (2011 - 2012)

Acadia Pharmaceuticals' (ACAD) quarterly Current Leases came in at $3000.0 in Q3 2012, down 76.92% quarter-over-quarter from $13000.0 in Q2 2012.

Acadia Pharmaceuticals (ACAD) Current Leases (2011 - 2012) Analysis & Trends

Acadia Pharmaceuticals' Current Leases history runs 2 years deep, the most recent figure standing at $3000.0 for Q3 2012.

On a quarterly basis, Current Leases changed N/A year-over-year to $3000.0 in Q3 2012; TTM through Sep 2012 was $3000.0, a N/A change from a year earlier, with the FY2011 full-year figure at $32000.0, changed N/A from the prior year.
Current Leases retreated to $3000.0 in Q3 2012 per ACAD's latest filing, from $13000.0 in the prior quarter.
Across five years, Current Leases topped out at $32000.0 in Q4 2011 and bottomed at $3000.0 in Q3 2012.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Current Leases (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	531,233.95
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	20.58 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	872,589.03
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	720.00 Mn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	11.00 Mn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	16.61 Mn
10	Acadia Pharmaceuticals	4.23 Bn	3.38 Bn	243.27 Mn	-

Download Data